Urinary proteomics in obstructive sleep apnoea and obesity

Abstract

In this study, we report for the first time, urinary proteomic profile analyses using CE-MS in OSA and non-OSA obese groups. The differences in urinary proteomic profiles prior to adjustment for multiple testing, with increased metabolic syndrome in obese OSA subjects, suggest that there may be a role for CE-MS in characterising urinary profiles in severely obese populations with OSA.

Overview of proteomics studies in obstructive sleep apnea

“…During revision of this manuscript we came across the work of Seetho et al reporting urinary proteomics profiling in OSA and non-OSA obese adult patients using CE–MS technology [62]. The data showed 24 peptides that were differentially abundant (p < 0.01) between patient groups, although these differences did not reach significance after adjustment for multiple statistical testing to account for false positives (false discovery rate).…”

Research update for articles published in EJCI in 2014

“…X [81] These results suggest that the magnitude of the flow-mediated dilation and its latency are both important for identifying patients at risk of cardiovascular disease. Subjects with a delayed however significant vasodilation associated with a blunted early response exhibit the highest cardiovascular risk X [86] In this study, we report for the first time, urinary proteomic profile analyses using capillary electrophoresis-mass spectrometry (CE-MS) in obstructive sleep apnoea (OSA) and non-OSA obese groups. The differences in urinary proteomic profiles prior to adjustment for multiple testing, with increased metabolic syndrome in obese OSA subjects, suggest that there may be a role for CE-MS in characterizing urinary profiles in severely obese populations with OSA X [88] In patients with coronary artery disease (CAD), dilated left ventricular hypertrophy (LVH) and nondilated LVH provide distinct prognostic information.…”

Recent developments in capillary and microchip electroseparations of peptides (2013–middle 2015)

“…Other examples of CE‐MS applications include determination of a toxic dipeptide γ‐glutamyl‐S‐ethenyl‐cysteine in the extract of the legume plant Vicia narbonensis seeds by CE‐ESI‐IT‐MS/MS using a target‐based approach , and identification of urinary peptide biomarkers associated with rheumatoid arthritis or with obstructive sleep apnoea and obesity .…”